Rigel | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

50 results for “Rigel”

Trials

View all 16 →

Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

624 participants · First posted Dec 9, 2008

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

81 participants · First posted Feb 21, 2024

Trial of Fistula Versus Graft in Elderly Patients

21 participants · First posted Sep 12, 2018

Drugs

GDF8 inhibitor (Rigel Pharmaceuticals)

microtubule polymerization-inhibiting thienopyrimidine derivatives (Rigel Pharmaceuticals)

TRIGEL

Organizations

Rigel Pharmaceuticals

India

Rigel Pharmaceuticals, Inc.

United States

Rogel Cancer Center: University of Michigan

United States

News

View all 22 →

Rigel Pharmaceuticals Reports Strong Growth Across Oncology Portfolio with 44% Revenue Increase

Rigel Pharmaceuticals Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer to Drive Oncology Pipeline

Rigel Pharmaceuticals Reports Strong Growth with TAVALISSE and REZLIDHIA in 2024, Expands Global Reach

Page 1 of 5